National Drug Abuse Treatment Clinical Trials Networklib.adai.washington.edu/ctnlib/pdf/webinar2016.pdf · to share and exchange clinical research knowledge. We have developed a series

National Drug Abuse Treatment Clinical Trials Network

CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE

2016 Web Seminar

Series CO

UR

SE

CA

TA

LO

G

CTN Web Seminar Series: A Forum to Exchange Research Knowledge

2

LETTER TO READERS

Dear CTN Members,

The CTN Web Seminar Series is a forum for network members to share and exchange clinical research knowledge. We have developed a series of webinars for 2016 on topics of particular interest to our CTN members, such as the conduct of clinical investigations, privacy protections, data analyses, treatment methodologies, investigator tools, drug accountability, and other topics for research trials.

We thank our presenters and network members, who graciously volunteer their time, knowledge, and expertise to contribute to our CTN-wide learning environment. Additionally, this series is made possible through the support and funding of our sponsor and the participation of our CTN members and their affiliates.

Please enjoy the 2016 training program.

Tracee Williams

CTN Training Coordinator

This training has been funded in whole or in part with Federal funds from the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services,

under Contract No. HHSN271201500065C.

CTN Web Seminar Series: A Forum to Exchange Research Knowledge WEB SEMINAR SERIES 2016

3

TABLE OF CONTENTS

WEB SEMINAR PAGE

Privacy and Confidentiality Protections for Research Participants with Substance Use Disorders: 42 CFR Part 2 Revisions

4

The Challenge of Evidence-Based Group Therapy for Substance Use Disorders 6

CTN Investigator Toolbox - An Orientation 8

CTN-0044 WEB-TX: A Review of the Primary and Secondary Outcomes 10

In The Weeds: Assessing Neurocognitive Brain Imaging and Substance Abuse Measures in Emerging Adults 13

Pharmacotherapy Trials for Adolescent Substance Use Disorders: From Concept to Execution 15

Demonstrating Practical Use of Data Share and Secondary Analyses 16

Preparation for Drug Management and Accountability in a CTN Clinical Trial 18

Perceptions of Harm and Addiction of Snus 20

Training Resources 22

NDAT CTN Clinical Coordinating Center (CCC) and Data and Statistics Center (DSC) 23


4

PRIVACY AND CONFIDENTIALITY PROTECTIONS FOR RESEARCH PARTICIPANTS WITH SUBSTANCE USE DISORDERS: 42 CFR PART 2 REVISIONSWednesday, March 9, 2016 at 12:00 pm ET

SEMINAR DESCRIPTION:Maintaining the privacy and confidentiality of research participants is a critical aspect of conducting quality research investigations and reflects compliance with Good Clinical Practice guidelines and regulations. There are specific rules and protections established for nondisclosure of research and medical records of study participants with substance use disorders (SUDs) and currently changes proposed to ensure the privacy protections sufficiently meet the needs of a changing healthcare environment. This one-hour course will acquaint attendees with 42 CFR Part 2 privacy protections, discuss the proposed changes, and implications for SUD treatment programs and healthcare provider interactions in various clinical settings.

LEARNING OBJECTIVES:• Describe the basic privacy protections afforded by 42 CFR Part 2, what

information is protected, and to whom the regulations apply.• Review the proposed changes to 42 CFR Part 2 as substance abuse

treatment becomes increasingly available in non-traditional medical settings.

• Consider implications of the proposed changes to substance use data flow between health organizations for research and medical records.

TARGET AUDIENCE:Everyone is welcome! This webinar is targeted to all staff engaged in the conduct of substance use treatment and research.


5

MAUREEN BOYLE, PHD

Dr. Maureen Boyle is the Chief of the Science Policy Branch in NIDA’s Office of Science Policy and Communications. Prior to joining NIDA, Dr. Boyle was a Lead Public Health Advisor for Health Information Technology (HIT) at the Substance Abuse and Mental Health Services Administration (SAMHSA) where she coordinated efforts to promote the use of technology to improve the delivery of substance abuse treatment. Prior to joining SAMHSA Dr. Boyle was an American Association for the Advancement of Science (AAAS) Science and Technology Policy Fellow serving at the National Institutes of Health, Office of Behavioral and Social Sciences Research (OBSSR). In

this role she led multiple initiatives to improve data collection and clinical quality measurement within behavioral health. Dr. Boyle received her PhD in neuroscience from Washington University in St. Louis where she studied the genetic and molecular basis of depression and anxiety-related behaviors. She completed a postdoctoral fellowship at the Allen Institute for Brain Science where she investigated neuropathological, molecular, and genetic abnormalities in Autistic children and animal models of autism.

CARMEN ROSA, MS

Ms. Carmen Rosa works at the Center for Clinical Trials Network, within the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). She has been with NIDA since 1999, when NIDA started the National Drug Abuse Treatment Clinical Trials Network (CTN). Since then, she has held several roles overseeing the Network’s research management and implementation. Currently, Ms. Rosa serves as Regulatory Officer at the CCTN providing regulatory consultations to investigators and NIDA staff. Her

other major responsibilities include working with CTN staff and investigators in developing and implementing clinical trials, managing Protocol Review and Data and Safety Monitoring Boards that review and oversee various multi-site trials, coordinating the CTN international activities, and serving as an advocate for women and minority participation in research.


6

THE CHALLENGE OF EVIDENCE-BASED GROUP THERAPY FOR SUBSTANCE USE DISORDERSWednesday, March 23, 2016 at 1:00 pm ET

SEMINAR DESCRIPTION:The field of substance use disorder (SUD) treatment suffers from a “modality mismatch,” in which researchers primarily examine individual therapies even while real-world psychosocial clinicians primarily facilitate groups (especially open groups). Although understandable reasons exist for this state of affairs, group therapy is not diminishing anytime soon; moreover, clinicians may be ill-equipped at using evidence-based treatments (EBTs) in group format, given limited training along with non-trivial structural differences between modalities. This one-hour presentation includes a review of SUD group therapy research and clinical resources (including two CTN studies), with a focus on facilitators and barriers for using EBTs in group format.

LEARNING OBJECTIVES:• Describe at least two reasons for a treatment modality mismatch

between SUD research and real-world practice.• Identify at least two clinical resources for using evidence-based

treatments in group format.• Explain at least two facilitators and two barriers for using evidence-based

treatments in group format.

TARGET AUDIENCE:Everyone is welcome! This webinar is targeted to all clinicians, investigators, and clinical research staff.


7

DENNIS C. WENDT, PHD

Dr. Wendt is a postdoctoral research fellow with the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine, where he is mentored by Dr. Dennis Donovan (Pacific Northwest Node director). Dr. Wendt completed his PhD in Clinical Psychology at the University of Michigan and his clinical

internship at the Southwest Consortium in Albuquerque, New Mexico. His primary research interests pertain to evidence-based substance use disorder treatment, with a focus on group therapy and American Indian / Alaska Native populations.


8

CTN INVESTIGATOR TOOLBOX - AN ORIENTATIONWednesday, April 20, 2016 at 1:00 pm ET

SEMINAR DESCRIPTION:The Clinical Trials Network (CTN) Investigator Toolbox is a resource to investigators who are conducting studies within the CTN. The Toolbox provides templates for regulatory and other key study documents (e.g., Protocol Template, Form FDA 1572) and guidance on the tasks and processes associated with developing, implementing, and publishing a NIDA CTN clinical research study. This one-hour webinar will be a comprehensive review of the design of the website and resources made available to study investigators.

LEARNING OBJECTIVES:• Identify the location of the Investigator Toolbox. • Describe the sections and some of the main tools and documents within

each section of the Toolbox.• Understand the ways in which the Toolbox can be used as a resource for

those involved in developing, implementing, and managing clinical trials.

TARGET AUDIENCE:Everyone is welcome! This training is targeted to Investigators, Project Directors, and all research staff engaged in development, implementation, and closeout activities for CTN studies and sites.

DIKLA BLUMBERG, PHD

Dr. Blumberg is the Project Manager for the National Drug Abuse Treatment Clinical Trials Network (NDAT CTN) Clinical Coordinating Center at The Emmes Corporation. She is a Social Psychologist with expertise in self-regulation processes and over 10 years of experience in behavioral research. Previously, Dr. Blumberg worked in a NIDA-funded Postdoctoral Traineeship in Drug Abuse Treatment and Services Research at UCSF, where she designed and implemented a series

of experiments investigating self-regulation processes involved with tobacco dependence. Additionally, she worked on a Cancer Research Training Award at the National Cancer Institute’s Behavioral Research Program, where she was involved with projects designed to better understand health behaviors and their underlying processes.


9

CARMEN ROSA, MS

Ms. Carmen Rosa works at the Center for Clinical Trials Network, within the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). She has been with NIDA since 1999, when NIDA started the National Drug Abuse Treatment Clinical Trials Network (CTN). Since then, she has held several roles overseeing the Network’s research management and implementation. Currently, Ms. Rosa serves as Regulatory Officer at the CCTN providing regulatory consultations to investigators and

NIDA staff. Her other major responsibilities include working with CTN staff and investigators in developing and implementing clinical trials, managing Protocol Review and Data and Safety Monitoring Boards that review and oversee various multi-site trials, coordinating the CTN international activities, and serving as an advocate for women and minority participation in research.


10

CTN-0044 WEB-TX: A REVIEW OF THE PRIMARY AND SECONDARY OUTCOMESWednesday, May 25, 2016 at 1:00 pm ET

SEMINAR DESCRIPTION:The National Drug Abuse Treatment Clinical Trials Network WEB-TX study is one of the largest randomized controlled trials to date examining the effectiveness of an internet-delivered treatment intervention on clinical outcomes among people receiving outpatient substance abuse treatment. In addition to the primary outcome analysis showing significant improvements in abstinence and treatment retention among people randomized to the internet-delivered treatment arm, the study has produced three methodological publications, four baseline publications, five secondary outcome publications, and an additional seven secondary outcome publications under review or in preparation. The purpose of this one-hour webinar is to present a synthesis of WEB-TX study findings, focusing on key secondary clinical outcomes, and discuss new areas of research for technology-based treatments for substance use disorders.

LEARNING OBJECTIVES:• Understand the design and methodological decisions critical to the

implementation of an effectiveness trial of a technology-based intervention.• Review the primary outcomes and key secondary outcomes of the WEB-TX

study.• Discuss new areas of research for technology-based interventions.

TARGET AUDIENCE:Everyone is welcome! This webinar is targeted to investigators, research staff, and community providers interested in technology-based interventions for substance use disorders.

EDWARD V. NUNES, JR., MD

Dr. Nunes is a Professor of Psychiatry and Principal Investigator of the Greater New York Node of the National Institute on Drug Abuse (NIDA) Clinical Trials Network as well as other NIDA funded studies on behavioral and medication treatments for substance dependence and related psychiatric disorders. Interests and ongoing

studies include treatments for cocaine dependence in general, heroin and other opioid dependence, for nicotine dependence in general, and for addicted patients with co-occurring psychiatric disorders


11

including depression, and post-traumatic stress disorder. Types of treatment under study include medication treatments (naltrexone, buprenorphine, mirtazapine) as well as behavioral and psychotherapeutic approaches and computer-delivered treatments. Dr. Nunes also studies the challenges involved in implementing evidence-based treatments for

substance use disorders in real-world community-based treatment settings. Dr. Nunes also serves on the American Board of Addiction Medicine, Co-Chair of the Columbia/New York State Psychiatric Institute’s Institutional Review Board, and has been appointed to the National Advisory Council on Drug Abuse.

AIMEE CAMPBELL, PHD

Aimee Campbell, PhD, is a Research Scientist in the Substance Abuse Division of the New York State Psychiatric Institute (NYSPI) and an Assistant Professor of Clinical Psychiatric Social Work in the Department of Psychiatry at the Columbia University Medical Center. She was the Project Director for the NIDA Clinical Trials Network 0044 study. Her research interests center on the development and testing of behavioral interventions for substance use disorders and HIV prevention and treatment, including through use of technology-based platforms, with a specific emphasis on methods to improve access to and implementation of science-based treatments. Dr. Campbell’s work incorporates the personal, interpersonal, and social contexts in

which individuals manage the overlapping challenges of addiction, trauma, mental health disorders, and HIV sexual and drug risk behaviors. She has extensive experience in the development, implementation, and oversight of large community-based clinical trials. She has been involved in treatment research for substance use disorders, primarily in community settings and in partnership with community providers and consumers, for 20 years. Dr. Campbell completed undergraduate training in sociology at the University of Washington and received her master’s degree and doctorate from Columbia University School of Social Work.


12

IN THE WEEDS: ASSESSING NEUROCOGNITIVE BRAIN IMAGING AND SUBSTANCE ABUSE MEASURES IN EMERGING ADULTSWednesday, July 13, 2016 at 1:00 pm ET

SEMINAR DESCRIPTION:Multimodal studies which combine cognitive, clinical, neuroimaging and substance use assessments are critical to understanding the impact of substance use in emerging adults. These can be difficult, however, and a number of important yet confounding factors often cloud data collection. The goals of this one-hour presentation are to: 1) review the importance of collecting accurate and comprehensive information; 2) acknowledge the most common confounding variables; and 3) provide strategies for improving data collection among this population. These will be presented in conjunction with data and methodologic examples from ongoing NIDA and other funded studies.

LEARNING OBJECTIVES:• Define some of the difficulties associated with assessing substance use in

adolescent and emerging adult populations.• Recognize the importance of a clear study design with well-articulated

substance use assessment measures administered in a reliable, consistent, and comprehensive manner.

• Understand how to modify common tools for substance use assessment for a range of substances (i.e., TLFB).

• Identify a number of ways to improve the quality of data/information offered by adolescent/emerging adult research participants.

TARGET AUDIENCE:Everyone is welcome to attend!


13

STACI GRUBER, PHD

Dr. Staci Gruber is the Director of the Cognitive and Clinical Neuroimaging Core at McLean Hospital’s Brain Imaging Center and an Associate Professor of Psychiatry at Harvard Medical School. Dr. Gruber’s clinical and research focus is the application of neurocognitive models and multimodal brain imaging to better characterize neurobiological risk factors for substance abuse and psychopathology, particularly disruptions of the frontal network. In recent work, her lab has examined the etiologic bases of neural models of dysfunction in patients with bipolar disorder as well as marijuana-using adolescents and adults, the results of which have been published in numerous peer reviewed journals and been the basis of national and international symposia, documentaries and press conferences. Dr. Gruber has also been involved in the application of behavioral science to help shape

policies regarding juvenile advocacy and defense; her lab’s work in adolescent development was part of the Amicus brief leading to the Supreme Court’s landmark decision in Roper vs. Simmons, which states that it is unconstitutional to execute minors. Her ongoing initiative to educate policymakers, judges, attorneys and the general public in the differences between adults and adolescents and the impact of marijuana on the brain has already had both local and national impact on policy formation. She also directs the newly launched MIND (Marijuana Investigations for Neuroscientific Discovery) Program, designed to clarify the effects of medical marijuana on brain structure, function, and quality of life.


14

PHARMACOTHERAPY TRIALS FOR ADOLESCENT SUBSTANCE USE DISORDERS: FROM CONCEPT TO EXECUTIONWednesday, August 10, 2016 at 1:00 pm ET

SEMINAR DESCRIPTION:While several pharmacotherapies have been developed for substance use disorders (SUD) in adults, relatively few have been studied in adolescents, and complex design and execution issues must be addressed to optimize the potential impact of current and future research in this important area. This one-hour presentation will discuss method, design, and key strategies for the optimization of conduct/execution, overall treatment adherence, participant enrollment and retention, documentation, and management of adverse events for adolescent SUD pharmacotherapy trials. With adequate understanding of challenges and opportunities in the design and conduct of these trials, attendees will be equipped to incorporate this information into their research practices.

LEARNING OBJECTIVES:• Identify key issues in the conceptualization/design of pharmacotherapy trials

for adolescent substance use disorders (SUD).• Understand methods to optimize the management/execution of

pharmacotherapy trials for adolescent SUD.• Consider strategies to standardize design methods across adolescent SUD

pharmacotherapy trials.

TARGET AUDIENCE:Everyone is welcome! This webinar is targeted to all investigators, clinicians, statisticians, and research staff engaged in the planning and development of pharmacotherapy trials.


15

KEVIN M. GRAY, MD

Dr. Gray is Professor and Director of Child and Adolescent Psychiatry at the Medical University of South Carolina in Charleston, South Carolina. Dr. Gray maintains active clinical practice and conducts National Institutes of Health sponsored clinical research on substance use disorders in adolescents and young adults, with particular emphasis on treatment development

for cannabis and tobacco use disorders in youth. With a multidisciplinary group of collaborators, Dr. Gray investigates biobehavioral mechanisms underlying substance use disorders, and works to apply these findings to real world clinical practice.


16

DEMONSTRATING PRACTICAL USE OF DATA SHARE AND SECONDARY ANALYSESWednesday, September 14, 2016 at 1:00 pm ET

SEMINAR DESCRIPTION:The NIDA Data Share website was created to make CTN data available to the scientific community and the public at large. These data can be used for secondary analyses and thus serve to increase the contribution of the original studies conducted and extend findings into new areas and knowledge for the benefit of public health. This one-hour presentation will focus on an overview of the website, provide highlights of its structure and contents, and detail the technical procedures involved in utilizing the data for secondary analyses.

LEARNING OBJECTIVES:• Review the structure of the NIDA Data Share website.• Understand the information provided, how to navigate through the

website, and obtain all the relevant information.• Demonstrate the technical procedures for using SAS or ASCII data sets

for conducting secondary analyses.

TARGET AUDIENCE:Everyone is welcome! This webinar is targeted to all research professionals responsible for the development of research trials and those interested in secondary analyses and expanding their use of CTN trial data sets.

ABIGAIL MATTHEWS, PHD

Dr. Matthews joined The Emmes Corporation in January 2010 and provides statistical support for several projects, including the National Drug Abuse Treatment Clinical Trials Network (NDAT CTN). As a post-doctoral associate at the University of Pittsburgh, she began research in the genetics of alcohol dependence and engaged in analyses of psycho-logical characteristics in childhood predicting future alcohol abuse and dependence. At Rockefeller University, Dr. Matthews collaborated

with researchers at a major pharmaceutical company where she performed pharmacoge-nomic analyses to predict which subjects would respond to a particular drug and identify subjects at higher risk of side effects due to that medication. She also has experience working with registry data as a research assistant consulting with the Cancer Genetics Network.


17

DIKLA BLUMBERG, PHD

Dr. Blumberg is the Project Manager for the National Drug Abuse Treatment Clinical Trials Network (NDAT CTN) Clinical Coordinating Center at The Emmes Corporation. She is a Social Psychologist with expertise in self-regulation processes and over 10 years of experience in behavioral research. Previously, Dr. Blumberg worked in a NIDA-funded Postdoctoral Traineeship in Drug Abuse Treatment and Services Research at UCSF, where she designed and implemented a series

of experiments investigating self-regulation processes involved with tobacco dependence. Additionally, she worked on a Cancer Research Training Award at the National Cancer Institute’s Behavioral Research Program, where she was involved with projects designed to better understand health behaviors and their underlying processes.


18

PREPARATION FOR DRUG MANAGEMENT AND ACCOUNTABILITY IN A CTN CLINICAL TRIAL Wednesday, October 19, 2016 at 1:00 pm ET

SEMINAR DESCRIPTION:In preparation for the conduct of a clinical trial, investigators must plan for the management of medications used as an intervention or a supportive drug. In setting up for a study, there are various aspects to consider for implementation, tracking, and quality assurance. This one-hour seminar will discuss drug management planning and implementation considerations for trials in the CTN.

LEARNING OBJECTIVES:• Describe drug management planning and preparation activities.• Discuss tools for drug inventory and drug accountability tracking.• Define implementation challenges and quality assurance.

TARGET AUDIENCE:Everyone is welcome! This session is targeted to research staff with responsibilities for drug management planning and implementation in clinical trials.

PATRICIA NOVO, MPA, MPH

Patricia “Patsy” Novo is an Assistant Research Scientist in the Department of Psychiatry at NYU’s School of Medicine where she is responsible for project planning and resource allocation for clinical trials in mental health and addiction. Patsy has been part of the CTN since its earliest days and is currently the National Project Manager for the CTN-0051 study. Prior to joining the staff at NYU, she provided technical assistance to non-profit organizations, planned projects

to improve women’s health in developing countries, and was part of the founding team of Action Without Borders/idealist.org, among other work activities. Patsy has a BS degree from Cornell University, an MPA in Management from the Wagner School of Public Service at NYU, and a Master’s degree in Global Public Health from NYU.


19

BETH JEFFRIES, BS, CCRP

Beth Jeffries is a Protocol Monitor for the National Drug Abuse Treatment Clinical Trials Network (NDAT CTN) Clinical Coordinating Center at The Emmes Corporation. Since 2008, she has been providing Quality Assurance (QA) support on numerous CTN drug and non-drug studies, with responsibilities for monitoring and reporting, providing guidance and training to site staff on protocol adherence, regulatory, safety, and other site/study specific concerns as well as providing study set-up and implementation

support services. Previously, Beth worked as a clinical research associate, research program coordinator, and laboratory technician with the National Cancer Institute and other research organizations. Beth obtained a BS degree in Biology from Bennett College, and she is CCRP certified by the Society of Clinical Research Associates (SOCRA).


20

PERCEPTIONS OF HARM AND ADDICTION OF SNUSWednesday, November 30, 2016 at 1:00 pm ET

SEMINAR DESCRIPTION:Changes in public attitudes toward smoking have led to reductions in cigarette consumption in the United States. Tobacco companies in the United States are prohibited from making reduced harm claims without filing a modified risk tobacco product application with the Food and Drug Administration and obtaining an order to market as such. However, product marketing may suggest reduced risk to individuals. This study examines perceptions, in particular those related to harm and addiction, of snus print advertisements. A mixed-methods design combined eye-tracking, survey, and semi-structured interviews. Results from the study may provide a better understanding of how smokers perceive and understand products after viewing advertisements, which may guide public health efforts to educate smokers on the risks of emerging products.

LEARNING OBJECTIVES:• Review information about tobacco regulation in the U.S., current and

historical trends in tobacco use in the U.S., harm perceptions, and health outcomes associated with tobacco use.

• Discuss the purpose, design, and methods of a mixed methods study examining how print advertising may influence perceptions about snus.

• Report study outcomes and future directions.

TARGET AUDIENCE:Everyone is welcome!


21

ANNETTE KAUFMAN, PHD

Dr. Kaufman is a Health Scientist and Program Director in the Tobacco Control Research Branch (TCRB), Behavioral Research Program (BRP), Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI). She obtained her Doctorate in Applied Social Psychology from The George Washington University and Master of Public Health in quantitative methods from the Harvard School of Public Health. She completed her post-doctoral training as a Cancer Prevention Fellow in the Office of the Director (OAD) in the Behavioral Research Program. Dr. Kaufman

is actively involved in the development and implementation of the Health Information National Trends Survey (HINTS) and the Population Assessment of Tobacco and Health (PATH) study. Her program of research focuses on tobacco product harm judgments and risk perceptions associated with tobacco use. Dr. Kaufman is particularly interested in the influence of policy on tobacco beliefs and behavior.

22

TRAINING RESOURCES DID YOU MISS A WEB SEMINAR?

All seminar recordings, presentations, and training materials are available on the CTN Dissemination Library’s training website at http://www.ctndisseminationlibrary.org/ctntraining.htm.

GOOD CLINICAL PRACTICE TRAINING GCP training prepares study staff responsible for critical aspects of study conduct. Per CTN Policies and Procedures, all study staff is required to complete such training, subject to renewal every three (3) years. Reference the CTN GCP Online training website here: https://gcp.nidatraining.com.

PROTECTING HUMAN RESEARCH PARTICIPANTS This two-hour web-based course is designed for conducting research and presents information on the rights and welfare of human research participants. It satisfies the NIH human subjects training requirement for obtaining federal funds, subject to renewal every three (3) years. A certificate is available upon completion: http://phrp.nihtraining.com.

DEMOGRAPHICS The training is available on http://ctndisseminationlibrary.org/ctntraining.htm. Requests for quiz grading and completion certificates may be directed to [email protected].

CONTINUING EDUCATION (CEU) RESOURCE For continuing education credits, reference the Society of Clinical Research Associates (SoCRA) website here: http://www.socra.org/html/certific.htm.

ASI LITE DO YOU NEED TRAINING? Contact us at [email protected] to arrange for a trainer.


23

WEB SEMINAR SERIES 2016

NDAT CTN CLINICAL COORDINATING CENTER (CCC)

E-MAIL: Inquiries or Supplies [email protected] Regulatory Documents [email protected] Safety Related Events [email protected] Training Inquiries [email protected] Main Fax Number ..................................301-576-3924

THE CLINICAL COORDINATING CENTER CAN COORDINATE TRAINING OR PROVIDE TRAINING MATERIAL AS NEEDED FOR THE FOLLOWING: • Addiction Severity Index (ASI) • Composite International Diagnostic Interview (CIDI) v2.1 • Risk Behavior Survey (RBS)

Please contact [email protected].

NDAT CTN Data and Statistics Center (DSC) Group E-mail [email protected] Main Fax Number ..................................800-416-2017 Website URL ..........................................www.ctndsc2.com

DSC HELP DESK CONTACT INFORMATION Monday-Friday (8:00 am to 8:00 pm ET) Help Desk .............................................888-337-7071 (toll-free) Help Desk E-mail [email protected] Staff ID Request Form is located on the DSC 2 (Emmes) page on Livelink. Other Help Desk Support

• Request access to Livelink • Request access to CTN Clinical Trials Report Website • AdvantageEDC issues/inquiries • Protocol-specific inquiries • Protocol-specific system issues/inquiries


National Drug Abuse Treatment Clinical Trials Network

CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE

INSIDE THE 2016 WEB SEMINAR SERIES

COURSE TITLE DATE

Privacy and Confidentiality Protections for Research Participants with Substance Use Disorders: 42 CFR Part 2 Revisions

MAR 9

The Challenge of Evidence-Based Group Therapy for Substance Use Disorders

MAR 23

CTN Investigator Toolbox - An Orientation APR 20

CTN-0044 WEB-TX: A Review of the Primary and Secondary Outcomes

MAY 25

In The Weeds: Assessing Neurocognitive Brain Imaging and Substance Abuse Measures in Emerging Adults

JUL 13

Pharmacotherapy Trials for Adolescent Substance Use Disorders: From Concept to Execution

AUG 10

Demonstrating Practical Use of Data Share and Secondary Analyses

SEP 14

Preparation for Drug Management and Accountability in a CTN Clinical Trial

OCT 19

Perceptions of Harm and Addiction of Snus NOV 30